A kind of glycoside compound microemulsion soft capsule and preparation method thereof

Through the preparation of glycoside compound microemulsion soft capsules, the combination of specific solvents and emulsifiers is used to solve the problem of unstable glycoside compounds in the preparation, significantly improving its effect in the treatment of ischemic stroke, and achieving brain deficiency Effective protection of blood.

CN117017936BActive Publication Date: 2024-11-19HEHUANG PHARMA SHANGHAI
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202311194727.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-15
Publication Date
2024-11-19
Estimated Expiration
2043-09-15

AI Technical Summary

Technical Problem

Glycoside compounds have unstable factors such as oxidation, hydrolysis, and cleavage during the preparation process, resulting in the difficulty of drug preparation in the treatment of ischemic stroke.

Method used

The preparation method of glycoside compound microemulsion soft capsules is adopted. By mixing glycoside compounds with solvents, emulsifiers and co-emulsifiers in a specific proportion, a microemulsion preparation is formed and filled into the soft capsules, using polyethylene glycol and polyethylene glycol. Hydrogenated oxyethylene castor oil, sorbitan and other ingredients improve stability.

Benefits of technology

It significantly improves the stability and therapeutic effect of glycoside compounds, has a significant neuroprotective effect on stroke, significantly improves the neurological function after cerebral ischemia injury in rats and reduces the volume of cerebral infarction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

The invention belongs to the field of medical technology, and specifically relates to a glycoside compound microemulsion soft capsule and a preparation method thereof, which discloses a preparation method of a glycoside compound microemulsion soft capsule, comprising contents and soft capsules, wherein the contents include glycoside compounds, solvents, emulsifiers and co-emulsifiers, wherein the mass ratio of glycoside compounds: solvents: emulsifiers: co-emulsifiers is 1: (0.5-20): (1-20): (0.5-20), the glycoside compound microemulsion soft capsule of the present invention has stable quality under accelerated stability test conditions, and the total impurity content varies with different auxiliary materials, which shows that the glycoside compound microemulsion soft capsule has specific requirements for auxiliary materials. The infarction volume after cerebral ischemic injury in rats can be significantly reduced, the cerebral ischemic injury rats have obvious neuroprotective function, and have cerebral ischemia therapeutic effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and in particular relates to a glycoside compound microemulsion soft capsule and a preparation method thereof. Background Art

[0002] A study by the World Health Organization shows that cerebrovascular disease is not only the second leading cause of death in the world, accounting for 9.6% of all causes of death, but also the number one factor in adult disability. In 2005, the incidence and mortality of stroke in my country ranked first in the world; in 2008, the number of deaths from stroke in the country reached 1.5 million. Thrombolytic anticoagulant therapy, surgical operations and endovascular treatment can reduce the incidence and high mortality of cerebrovascular disease and effectively prevent the recurrence of stroke. Although thrombolysis can make the ischemic area get blood supply as soon as possible, its application is limited due to the strict time window (within 3-4.5 hours after onset) and possible adverse reactions such as reperfusion injury and increased risk of bleeding. In the clinical practice, relatively few patients can actually receive treatment. For the acute stage of ischemic stroke, a variety of measures are mainly used to improve cerebral blood circulation and neuroprotective drugs for treatment. The drugs used to improve cerebral blood circulation in China mainly include butylphthalide and human urinary kininogen. As for drugs with neuroprotective effects, there are not many drugs currently used in clinical practice. At present, there is a shortage of drugs for the treatment of acute ischemic stroke, and there is an urgent need to increase scientific research efforts to research and develop new drugs with therapeutic effects and fewer side effects. The research and development of drugs for the treatment of stroke is active both at home and abroad, and there is a large demand for drugs for the treatment of stroke in clinical practice.

[0003] The previously applied Chinese patent CN109988201B discloses a glycoside compound of formula I; Chinese patent CN112625073B discloses a method for preparing the glycoside compound; Chinese patent CN109988200B discloses that the glycoside compound can be used to prevent and treat ischemic cerebrovascular diseases, especially stroke; Chinese patent CN109988202B discloses that the glycoside compound can be used to prevent and treat lower limb ischemic microcirculatory disorders, especially diabetic foot diseases. Studies have found that the glycoside compound can achieve neuroprotective effects by inhibiting the excitotoxicity and oxidative stress damage of nerve cells caused by hypoxia and regulating the expression of inflammatory factors and neurotrophic factors in cells, thereby achieving the effect of treating ischemic stroke. Therefore, it provides a reliable guarantee for the research of drugs for treating ischemic cardiovascular and cerebrovascular diseases, especially cerebral infarction (stroke), myocardial infarction, and lower limb ischemic microcirculatory disorders.

[0004] Glycoside compounds are prone to unstable factors such as oxidation, hydrolysis, and cleavage during the preparation process. How to better formulate glycoside compounds for the treatment of ischemic stroke recovery period is a difficult problem. Summary of the invention

[0005] In a first aspect, the present invention provides a glycoside compound microemulsion soft capsule, which comprises a capsule and contents, wherein the capsule comprises a soft capsule or a hard capsule, and the contents comprise a glycoside compound, a solvent, an emulsifier and an emulsifier aid.

[0006] Furthermore, the glycoside compound is a compound represented by Formula I.

[0007]

[0008] Furthermore, the solvent is selected from one or more of polyethylene glycol 400 (PEG400), polyethylene glycol 200 (PEG200), glycerol, water, and propylene glycol (PG).

[0009] Furthermore, the emulsifier is selected from one or more of polyoxyethylene 40 hydrogenated castor oil (Kolliphor RH40), polyoxyethylene 35 hydrogenated castor oil (Kolliphor EL), monolinoleyl glyceryl (Maisine cc), caprylic / capric mono-, di- and tri-glycerides (Capmul MCM).

[0010] Furthermore, the co-emulsifier is selected from one or more of sorbitan oleate (Span 80), polysorbate 80 (Tween 80), caprylic / capric macrogol glyceride (Labrasol), propylene glycol monocaprylate (Captyol 90), and peanut oil.

[0011] In a second aspect, the present invention provides a pharmaceutical composition comprising a glycoside compound, a solvent, an emulsifier, and an emulsifier aid.

[0012] The glycoside compound is a compound shown in formula I.

[0013] The solvent is selected from one or more of polyethylene glycol 400 (PEG400), polyethylene glycol 200 (PEG200), glycerol, water, and propylene glycol (PG).

[0014] The emulsifier is selected from one or more of polyoxyethylene 40 hydrogenated castor oil (Kolliphor RH40), polyoxyethylene 35 hydrogenated castor oil (Kolliphor EL), monolinoleyl glyceryl (Maisine cc), caprylic / capric mono-, di- and tri-glycerides (Capmul MCM).

[0015] The auxiliary emulsifier is selected from one or more of sorbitan oleate (Span 80), polysorbate 80 (Tween 80), caprylic / capric macrogol glyceride (Labrasol), propylene glycol monocaprylate (Captyol 90), and peanut oil.

[0016] In a third aspect, the present invention provides a method for preparing glycoside compound microemulsion soft capsules.

[0017] The preparation method of the glycoside compound microemulsion soft capsule comprises the following steps:

[0018] S1. Weigh the raw material: glycoside compound of formula I, solvent, emulsifier and co-emulsifier;

[0019] S2. The mass ratio of the glycoside compound: solvent: emulsifier: co-emulsifier is 1: (0.5-20): (1-20): (0.5-20).

[0020] S3. The substances described in S2 are uniformly mixed at room temperature according to the proportions described above to obtain a glycoside compound microemulsion preparation.

[0021] S4. Filling the microemulsion preparation prepared in S3 into soft capsule shells to prepare the glycoside compound microemulsion soft capsules of the present invention.

[0022] In a fourth aspect, the present invention provides use of a microemulsion soft capsule of a glycoside compound in the preparation of a drug for treating stroke.

[0023] Furthermore, the glycoside compound is a compound of formula I.

[0024] Furthermore, the microemulsion soft capsule is a glycoside compound: solvent: emulsifier: co-emulsifier mass ratio of 1: (0.5-20): (1-20): (0.5-20), which is uniformly mixed at room temperature to obtain a glycoside compound microemulsion preparation, and the microemulsion preparation is filled into a soft capsule shell to obtain a glycoside microemulsion soft capsule.

[0025] Furthermore, the stroke is an acute cerebrovascular disease, which is a group of diseases that cause brain tissue damage due to sudden rupture of brain blood vessels or blockage of blood vessels that prevent blood from flowing into the brain. DETAILED DESCRIPTION

[0026] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0027] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0028] Example 1

[0029]

[0030] Preparation process: weigh a prescribed amount of the glycoside compound of formula I, add a prescribed amount of the glycoside compound of formula I, water, Capmul MCM and Span 80, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0031] Example 2

[0032]

[0033] Preparation process: weigh a prescribed amount of the glycoside compound of formula I, add a prescribed amount of the glycoside compound of formula I, water, Capmul MCM and Span 80, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0034] Example 3

[0035]

[0036] Preparation process: weigh a prescribed amount of the glycoside compound of formula I, add a prescribed amount of the glycoside compound of formula I, water, Capmul MCM and Span 80, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0037] Example 4

[0038]

[0039] Preparation process: weigh a prescribed amount of the glycoside compound of formula I, add a prescribed amount of the glycoside compound of formula I, water, Capmul MCM and Span 80, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0040] Example 5

[0041]

[0042]

[0043] Preparation process: weigh a prescribed amount of a glycoside compound of formula I, add a prescribed amount of a glycoside compound of formula I, water, Capmul MCM, Span 80 and Labrasol, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0044] Example 6

[0045]

[0046] Preparation process: weigh a prescribed amount of the glycoside compound of formula I, add a prescribed amount of the glycoside compound of formula I, PG, Capmul MCM, and Tween 80, fully dissolve and disperse evenly at room temperature to obtain a colorless and transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0047] Example 7

[0048]

[0049] Preparation process: weigh a prescribed amount of the glycoside compound of formula I, add a prescribed amount of the glycoside compound of formula I, PG, Maisine cc and Tween 80, fully dissolve and disperse evenly at room temperature to obtain a light yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0050] Example 8

[0051]

[0052]

[0053] Preparation process: weigh a prescribed amount of the glycoside compound of formula I, add a prescribed amount of the glycoside compound of formula I, PG, Capmul MCM, Tween 80 and Labrasol, fully dissolve and disperse evenly at room temperature to obtain a colorless and transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0054] Example 9

[0055]

[0056] Preparation process: weigh a prescribed amount of a glycoside compound of formula I, add a prescribed amount of a glycoside compound of formula I, PEG400, Kolliphor RH40, Tween 80 and Labrasol, fully dissolve and disperse evenly at room temperature to obtain a colorless and transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain the glycoside compound microemulsion soft capsule of the present invention.

[0057] Example 10

[0058]

[0059] Preparation process: weigh a prescribed amount of a glycoside compound of formula I, add a prescribed amount of a glycoside compound of formula I, water, peanut oil and Kolliphor EL, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain a glycoside compound microemulsion soft capsule.

[0060] Embodiment 11

[0061]

[0062]

[0063] Preparation process: weigh a prescribed amount of a glycoside compound of formula I, add a prescribed amount of a glycoside compound of formula I, water, Captyol 90 and Kolliphor EL, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain a glycoside compound microemulsion soft capsule.

[0064] Example 12

[0065]

[0066] Preparation process: weigh a prescribed amount of a glycoside compound of formula I, add a prescribed amount of a glycoside compound of formula I, water, medium-chain triglycerides and Solutol HS15, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain a glycoside compound microemulsion soft capsule.

[0067] Example 13

[0068]

[0069] Preparation process: weigh a prescribed amount of a glycoside compound of formula I, add a prescribed amount of a glycoside compound of formula I, water, Lauroglycol 90 and Gelucire 44 / 14, fully dissolve and disperse evenly at room temperature to obtain a yellow transparent glycoside compound microemulsion preparation; fill the microemulsion preparation into a soft capsule shell to obtain a glycoside compound microemulsion soft capsule.

[0070] Example 14 Sample stability test

[0071] The samples prepared in Examples 1 to 13 were placed at (40°C, RH75%) and subjected to stability tests. The results are shown in Table 1.

[0072] Table 1 Stability test of samples prepared in Examples 1 to 13

[0073]

[0074]

[0075]

[0076] Note: There is a significant difference between October and June, * indicates P < 0.01

[0077] The results show that the quality of the glycoside compound microemulsion soft capsule of the present invention is stable under the conditions of accelerated stability test. Glycoside compounds have unstable factors in the preparation process, among which the total impurity content of Examples 1-9 has no significant change, and the total impurity content of Examples 10-13 has significant changes. It can be seen that the microemulsion soft capsule preparation of glycoside compounds has specific requirements for excipients.

[0078] Example 15: Drug efficacy evaluation experiment in rats with permanent focal cerebral ischemia

[0079] 1. Experimental Materials

[0080] Drug preparation: According to the preparation process of Examples 1-9, glycoside compound microemulsion preparations of Formulations 1-9 were prepared, and blank control samples of microemulsion formulations 1-9 were prepared.

[0081] Experimental animals: 136 SD rats, SPF grade, male, about 300-330 g, 8-10 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0082] Feeding conditions: Feed: Cobalt 60 Irradiated sterilized SPF rat maintenance feed was purchased from Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd. Drinking water: Free drinking of homemade deionized water (water quality analysis including pH value, conductivity, microorganisms and heavy metals was performed once a quarter). Bedding: Corn cob bedding was purchased from Dezhou Gumei Agricultural Technology Co., Ltd.

[0083] 2. Animal model making

[0084] Male SD rats were selected for the efficacy experiment. They were anesthetized with isoflurane and fixed on the operating board with their backs facing up. The rectal temperature was controlled at 36-37℃ with a heating pad. The hair on the neck was cut and disinfected with iodine tincture. The skin was cut along the middle of the neck with an incision of about 1.5 cm. The subcutaneous tissue was separated with blunt forceps to avoid tissue bleeding, and the left common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) were exposed. The proximal and distal ends of the common carotid artery were ligated, and a slipknot was tied at the distal end (below the bifurcation of ICA and ECA). The distance between the two was about 1 cm, and the external carotid artery was ligated. A small incision was made at the CCA, and the thread plug was inserted. The slipknot at the distal end was loosened, and the thread plug was slowly pushed from the internal carotid artery to the front end of the middle cerebral artery. After obvious resistance was felt, the pushing action was stopped, the thread plug was fixed, the thread plug outside the blood vessel was cut, disinfected, and the wound was sutured.

[0085] This experiment requires 136 SD male rats, with a total of 17 groups: Sham group (sham operation), Model group (model group), 9 groups of microemulsion prescriptions 1-9, and 6 groups of microemulsion prescription blank control groups. The test samples are prescriptions 1-9 drug-containing microemulsion preparations and blank controls. The dosage of prescriptions 1-9 drug-containing microemulsions is 90 mg / kg, and the dosage of blank control samples is the same volume as the corresponding microemulsion drug-containing prescriptions. The dosage volume of microemulsions is calculated based on the dosage and rat weight before oral administration. The dosage for rats is 0.30 kg per rat.

[0086] The sham group and the model group were gavaged with 1.5 ml of 0.9% sodium chloride injection, respectively. In the rat model of permanent focal cerebral ischemia, the microemulsion preparations with different prescriptions were gavaged 30 minutes after ischemia, and the efficacy of administration was monitored for 14 days. The mNSS neurological function scores were performed on the 1st, 4th, 7th, 10th, and 14th days of administration. The forelimb grip strength test was performed on the 14th day of administration. After 14 consecutive days of administration, the rats were killed, and the rat cerebral infarction volume was observed and calculated by TTC staining to determine the therapeutic effect of microemulsions with different prescriptions on ischemic stroke.

[0087] 3. Observation indicators

[0088] In this experiment, the modified Neurological Severity Score (mNSS) method was used to score neurological deficits, with a total score of 18 points. The scoring criteria are detailed in Table 2.

[0089] Table 2 Nerve injury severity scores

[0090]

[0091]

[0092] In this experiment, the mNSS scoring method was used to comprehensively evaluate the motor, sensory, reflex and balance functions of animals. The neurological scores of rats in each group were recorded at the 1st, 4th, 7th, 10th and 14th days after surgery. The higher the score, the more severe the neurological damage. The scoring results are shown in Table 3.

[0093] 14 days after the rats were administered, they were anesthetized with isoflurane, blood was collected from the abdominal aorta, left to stand for 1 hour, centrifuged at 4°C, 4000rpm for 10 minutes, and the supernatant (serum) was taken and stored at -80°C for later use. After that, the rat brain was quickly taken out and placed in a -20°C refrigerator for 30 minutes. After being taken out, the olfactory bulb, cerebellum and brainstem were removed, and average coronal sections were cut into 6 slices with a thickness of about 2 mm. Then, the sections were quickly placed in 2% red tetrazolium (TTC) staining solution for section staining, incubated at 37°C in the dark for 7 minutes, and then the TTC solution was discarded after another 7 minutes of incubation. An appropriate amount of 4% paraformaldehyde was added, and the sections were fixed for 1 hour and then observed. Since the ischemic part of the brain slice is not stained, and the non-ischemic part appears red, a digital camera can be used to take pictures of the TTC-stained brain tissue slices, and the ischemic area in the rat brain tissue slices is calculated using Adobe Photoshop software, and the infarct volume is calculated according to the following formula. The results are shown in Table 4.

[0094]

[0095] Where h represents the thickness of each brain slice, and Sn and Sn+1 represent the infarct areas of adjacent brain slices, respectively.

[0096] GraphPad Prism 9.0 software was used to perform post-experimental data statistical analysis of various evaluation indicators of the efficacy experiment. The neurological score data were expressed as median ± interquartile range (IQR), and the cerebral infarction volume data were expressed as mean ± standard deviation (SD). The statistical differences of the data were analyzed by One-way analysis of variance (ANOVA), Two-way ANOVA and T-test. ***P<0.001; # P<0.05, ## P<0.01, ### P<0.001 indicates a significant difference. * Compared with the control group, # Compared with the model group. ns: P>0.05, indicating no significant difference.

[0097] 4. Experimental results

[0098] 4.1 Neurological function score

[0099] Table 3 Summary of mNSS neurological scores for 14 consecutive days of administration

[0100]

[0101]

[0102] Note: Two-way ANOVA statistical analysis. ***P<0.001; # P<0.05, ## P<0.01, ### P<0.001. * indicates that compared with the Sham group, # Compared with the Model group. All other P>0.05. N: The number of animals treated for 14 consecutive days.

[0103] According to the above table, compared with the Sham (sham operation) group, the neurological score of the Model group treated with 0.9% sodium chloride orally increased, indicating that the rat cerebral ischemic injury model (pMCAO) was successfully established. On the 4th day of administration, compared with the Model group, the rats orally administered microemulsions of prescriptions 1-9 can significantly reduce the neurological score and improve the neurological function defects; after 7 days of administration, the neuromotor behavior of pMCAO can be significantly improved; on the 10th and 14th days of administration, compared with the Model and each control group, the microemulsions of prescriptions 1-9 can significantly reduce the neurological score and improve the neurological function defects (***P<0.001; # P<0.05, ## P<0.01, ### P<0.001).

[0104] Based on the above data analysis, the microemulsion of prescription 1-9 at a dose of 90 mg / kg for 14 days can significantly improve the neuromotor behavior of pMCAO and has a therapeutic effect on cerebral ischemia.

[0105] 4.2 Cerebral infarction volume

[0106] Table 4 Summary of infarct volume results after 14 days of continuous administration

[0107]

[0108]

[0109] Note: One-way analysis of variance (ANOVA) statistical method. *** P < 0.001; # P<0.05, ## P<0.01. * Sham group

[0110] Compared with the Model group, # indicates compared with the Model group. All other P>0.05. N: the number of animals treated for 14 consecutive days.

[0111] According to the results in the table above, compared with the Sham group, the cerebral infarction volume of the rats in the Model group increased significantly, indicating that the pMCAO model was successfully established. Compared with the Model group and the control group, oral administration of the microemulsion of prescription 1-9 to rats significantly reduced the infarction volume after cerebral ischemia in rats ( *** P < 0.001; # P<0.05, ## P<0.01).

[0112] The above data analysis shows that the microemulsion prescriptions 1-9 can significantly reduce the infarct volume after cerebral ischemia in rats, have obvious neuroprotective function on rats with cerebral ischemia, and have a therapeutic effect on cerebral ischemia.

Claims

1. A glycoside compound microemulsion soft capsule, characterized in that: The glycoside compound microemulsion soft capsule comprises a capsule and contents, wherein the contents comprise a glycoside compound, a solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-di-triglyceride, and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glyceride; the solvent is selected from one or more of polyethylene glycol 400, polyethylene glycol 200, glycerol, water and propylene glycol; the mass ratio of the glycoside compound, the solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-di-triglyceride, and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glyceride is 1:(0.5-20):(1-20):(0.5-20); the glycoside compound is a compound shown in formula I: Formula I.

2. A glycoside compound microemulsion, characterized in that: The glycoside compound microemulsion comprises a glycoside compound, a solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-, di- and tri-glycerides, and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glycerides; the solvent is selected from one or more of polyethylene glycol 400, polyethylene glycol 200, glycerol, water and propylene glycol; the mass ratio of the glycoside compound, the solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-, di- and tri-glycerides, and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glycerides is 1:(0.5-20):(1-20):(0.5-20), and the glycoside compound is a compound shown in Formula I: Formula I.

3. A method for preparing a glycoside compound microemulsion soft capsule, characterized in that: The glycoside compound microemulsion soft capsule comprises a capsule and contents, wherein the contents comprise a glycoside compound, a solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-, di- and tri-glycerides, and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glycerides; the solvent is selected from one or more of polyethylene glycol 400, polyethylene glycol 200, glycerol, water and propylene glycol; the mass ratio of the glycoside compound, the solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-, di- and tri-glycerides, and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glycerides is 1:(0.5-20):(1-20):(0.5-20); the glycoside compound of formula I in the glycoside compound microemulsion soft capsule is: Formula I; The preparation method of the glycoside compound microemulsion soft capsule comprises the following steps: S1. Weigh the raw materials: glycoside compound of formula I, solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-, di- and tri-glycerides, and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glycerides; S2. The mass ratio of the glycoside compound of formula I, solvent, one or more of polyoxyethylene 40 hydrogenated castor oil and caprylic / capric mono-, di- and tri-glycerides and one or more of sorbitan oleate, polysorbate 80 and caprylic / capric macrogol glycerides is 1:(0.5-20):(1-20):(0.5-20); S3. The substances described in step S2 are uniformly mixed at room temperature according to the ratio to obtain a glycoside compound microemulsion preparation; S4. Filling the microemulsion preparation prepared in step S3 into soft capsule shells to prepare glycoside compound microemulsion soft capsules.

4. Use of the microemulsion soft capsule of glycoside compound as claimed in claim 1 in preparing a drug for treating stroke, characterized in that: The stroke is a disease in which blood cannot flow into the brain due to blood vessel blockage, causing brain tissue damage.

Citation Information

Patent Citations

  • Therapeutic agents used for the prevention and / or treatment of ischemic cerebrovascular diseases.

    CN109988200B

  • Glycosides, their preparation methods, compositions, applications and intermediates

    CN109988201B

  • Therapeutic agents for use in the prevention and / or treatment of diabetic foot disease

    CN109988202B

  • A method for preparing a glycoside compound

    CN112625073B

  • Water-in-oil type arbutin micro-emulsion and preparation method thereof

    CN111449981A